Clinical Investigation of the Bacterially-Derived Healon5 Ophthalmic Viscosurgical Device (OVD)
- Conditions
- Cataract
- Interventions
- Device: Investigational Healon5 OVDDevice: Healon5 OVD
- Registration Number
- NCT02782676
- Lead Sponsor
- Abbott Medical Optics
- Brief Summary
Prospective, multicenter, paired-eye, randomized, masked, clinical trial of the bacterially-derived Healon5 OVD versus the currently available Healon5 OVD control.
- Detailed Description
This study will include only subjects undergoing bilateral, primary, cataract extraction and intraocular lens (IOL) implantation and who meet all of the study inclusion and exclusion criteria in both eyes. Subjects who meet the inclusion/exclusion criteria and agree to participate will be randomly assigned to receive the investigational OVD in one eye and the currently-available (i.e., commercial) OVD in the fellow eye (control). Thus, a single group of subjects will provide data for both the investigational OVD and the control OVD.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 241
- Minimum 22 years of age
- Cataracts for which extraction and posterior IOL implantation have been planned for both eyes
- Potential for postoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or better
- Clear intraocular media, other than cataract
- Availability, willingness and sufficient cognitive awareness to comply with examination procedures
- Signed informed consent and HIPAA authorization
- Pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils)
- Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject
- Prior corneal refractive (LASIK- laser-assisted in situ keratomileusis, LASEK-laser-assisted sub-epithelial keratectomy, RK- radial keratectomy, PRK- photorefractive keratectomy, etc.) or intraocular surgery
- Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/40 Snellen during the study
- Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity losses to a level worse than 20/40 Snellen during the study.
- Conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects
- Use of systemic or ocular medications that may affect vision
- Prior, current, or anticipated use during the course of the 3-month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery)
- Poorly-controlled diabetes
- Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.).
- Known steroid responder
- Ocular hypertension of ≥ 20 mmHg, medically-controlled ocular hypertension (regardless of IOP value ), or glaucomatous changes in the optic nerve
- Endothelial cell count (ECC) lower than 1800 cells/mm2 preoperatively (based on the lowest value of the three cell counts as taken by the Konan Specular Microscope)
- Known ocular disease or pathology that may affect visual acuity or that may be expected to require retinal laser treatment or other surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.)
- Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes
- Concurrent participation, or participation within 45 days prior to preoperative visit, in any other clinical trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Investigational Healon5 OVD Investigational Healon5 OVD Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye. Approved Healon5 OVD Healon5 OVD Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
- Primary Outcome Measures
Name Time Method Mean Percent Endothelial Cell Count (ECC) Change Preoperatively vs. Postoperatively 3 months The mean percent ECC change with the bacterially-derived Healon5 will be statistically non-inferior to that with the animal-derived Healon5 control using a non-inferiority margin of 5%.
Cumulative Rates of Intraocular Pressure (IOP) Spikes 30mm of Mercury (mmHg) or Greater Measured Postoperatively 3 months The cumulative rate of IOP spikes with the bacterially-derived Healon5 will be statistically non-inferior to that with the animal-derived Healon5 control using a non-inferiority margin of 10%.
- Secondary Outcome Measures
Name Time Method Mean Change in IOP From Baseline 3 months The mean change in IOP from baseline for both OVD groups over time at the 6 hour, 1 day, 1 week, 1 month, and 3 month postoperative time points are presented.
Rate of IOP Spikes 30 mmHg or Greater at 3 Month Postoperatively 3 months The rate of IOP spike 30 mmHg or greater at 6 hour, 1 day, 1 week, 1 month and 3 months postoperatively was tabulated with frequency and proportion by OVD group.
Ocular Serious Adverse Events (SAE) 3 months Ocular serious and/or device related adverse event rates was be tabulated with the frequency and proportion of eyes with these events reported over time and cumulatively by OVD group.
\* in the results table denotes SAEs determined to be device-relatedGrade of Inflammation: Epithelial Edema Upto 3 months The grades of inflammation for epithelial edema was be tabulated with frequency and proportion of eyes with each grading for each event presented over time.
Grade of Inflammation: Stromal Edema Upto 3 months The grades of inflammation for stromal edema was be tabulated with frequency and proportion of eyes with each grading for each event presented over time.
Grade of Inflammation: Cells Upto 3 months The grades of inflammation for cells was be tabulated with frequency and proportion of eyes with each grading for each event presented over time.
Grade of Inflammation: Flare Upto 3 months The grades of inflammation for flare was be tabulated with frequency and proportion of eyes with each grading for each event presented over time.
Grade of Inflammation: Anterior Synechiae Upto 3 months The grades of inflammation for Anterior Synechiae was be tabulated with frequency and proportion of eyes with each grading for each event presented over time.
Grade of Inflammation: Posterior Synechiae Upto 3 Months The grades of inflammation for Posterior Synechiae was be tabulated with frequency and proportion of eyes with each grading for each event presented over time.
Grade of Inflammation: Fibrin Presence Upto 3 Months The grades of inflammation for Fibrin Presence was be tabulated with frequency and proportion of eyes with each grading for each event presented over time.
Trial Locations
- Locations (8)
Scott & Christie and Associates
🇺🇸Cranberry Township, Pennsylvania, United States
Empire Eye & Laser Center
🇺🇸Bakersfield, California, United States
Loden Vision Center
🇺🇸Goodlettsville, Tennessee, United States
Whitsett Vision Group
🇺🇸Houston, Texas, United States
Parkhurst NuVision
🇺🇸San Antonio, Texas, United States
Clarus Eye Centre
🇺🇸Lacey, Washington, United States
Katzen Eye Care & Laser Center
🇺🇸West Palm Beach, Florida, United States
Cape Coral Eye Center
🇺🇸Cape Coral, Florida, United States